Heartbeam (NasdaqCM:BEAT) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsBryan Humbarger - CCORobert Eno - Founder and Executive ChairmanTimothy Cruickshank - CFONone - Company RepresentativeConference Call ParticipantsBill Sutherland - Equity Research AnalystKyle Bauser - Equity Research AnalystLeo Carpio - Equity Research AnalystNone - AnalystOperatorGreetings, and welcome to the HeartBeam fourth quarter 2025 financial results conference call. At this time, all participants are in a ...

Shimmick (NasdaqCM:SHIM) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsTodd Yoder - CFOUral Yal - CEOConference Call ParticipantsAaron Spychalla - Senior Research AnalystGerard Sweeney - Managing Director and Senior Research AnalystUral YalGood afternoon, and thank you all for joining us on today's call. I'm joined by Todd Yoder, Shimmick's CFO. Before I get started, I would like to recognize the women and men who work at Shimmick, safely and effectively delivering the projects we tak ...

Financial Data and Key Metrics Changes - Total revenue for the second quarter was $8.3 million, up 18.3% year-over-year, marking the seasonally strongest quarter due to holidays [15] - Advertising revenue increased by 18.3% for the quarter, driven by strong growth in the Zedge Marketplace, despite lower ad revenue at Emojipedia [16] - GAAP loss from operations was $2.9 million, compared to a loss of $2.2 million last year, with a non-cash impairment charge of $3.7 million related to Emojipedia [21] - Non-GAAP net income was $0.8 million, with EPS of $0.06, compared to a loss of $0.2 million and a loss per share of $0.01 last year [21] - Cash flow from operations was $0.9 million, and free cash flow was $0.8 million for the quarter [21] - Cash strengthened to $19.1 million with zero debt, and the company generated solid free cash flow even after investments in innovation [13][22] Business Line Data and Key Metrics Changes - Zedge Marketplace revenue was up over 21% year-over-year, driven by strong advertising and subscription revenue [15] - Zedge Plus subscription revenue increased by 33% year-over-year, with the net active subscriber base growing by 49%, reaching nearly 1.2 million subscribers [17] - Deferred revenue reached $6 million, up 5% sequentially and 39% year-over-year, reflecting future revenue with a 100% gross margin [17] - Zedge Premium GTV was up 15.7% from the year-ago quarter, and ARPM increased by 47.6%, indicating improved monetization efficiency [18] Market Data and Key Metrics Changes - The company is experiencing MAU contraction but is focused on acquiring higher-value users and monetizing the audience more effectively [5] - The digital goods and services revenue includes contributions from both GuruShots and DataSeeds.AI, with the majority generated by GuruShots at this stage [19] Company Strategy and Development Direction - The company aims to strengthen monetization in the marketplace, build DataSeeds deliberately, and expand the innovation pipeline in a disciplined manner [14] - The operational focus is on building a high-quality outbound pipeline and better qualifying inbound requests to ensure long-term credibility in the enterprise market [9] - The company is exploring multimodal data, including images, audio, and video, to enhance its offerings [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the quality of monetization improving, leading to record results, and highlighted the importance of investments in ad inventory and subscription offerings [5] - The appetite for AI training data is described as insatiable, with the company focusing on productizing offerings to meet the needs of model builders [7] - Management acknowledged structural headwinds tied to the evolving field of search, particularly affecting Emojipedia, but noted that the business remains profitable [12] Other Important Information - The company launched two more alpha products, bringing the total to four out of six planned for the fiscal year, with a focus on modular development to accelerate product delivery [11][32] - The company is paying a quarterly dividend while continuing to invest in innovation and share repurchases when market conditions are favorable [22] Q&A Session Summary Question: Can you walk us through the DataSeeds pipeline and margin perspective? - Management indicated that the progression of a deal depends on the success of proof of concept, with margins being attractive but variable based on deal type [26][28] Question: How are you thinking about multimodal data? - The company is focusing on multimodal data, including images, audio, and video, with completed proof of concept on the video side and discussions on audio work [30] Question: Can you comment on the new alpha products? - The new products are being built on an evolving foundation to allow for modular development and faster market entry, with ongoing refinement in selecting what to produce next [31][32] Question: What is driving the momentum in subscription revenues? - The ongoing investment in optimizing subscription offerings and targeting prospective subscribers is driving the momentum [34] Question: What is driving the success of the Zedge Marketplace? - The fiscal Q2 coincides with year-end advertising spend, and efforts in data science to better segment users have contributed to the marketplace's success [36][38] Question: How is the Tapedeck product progressing? - The KPIs for Tapedeck are trending positively, with a focus on expanding the music catalog to attract users [42]

Nephros (NasdaqCM:NEPH) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAnthony Vendetti - Executive Managing Director of ResearchJudy Krandel - CFOKirin Smith - PresidentRobert Banks - President and CEOConference Call ParticipantsNone - AnalystOperatorGood afternoon, everyone, and welcome to the Nephros, Inc. fourth quarter 2025 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressin ...

Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 20.6% to $87.7 million compared to $110.5 million in Q4 2024 [14] - Full-year net sales were down 6.7%, totaling $368.3 million in 2025 versus $394.9 million in 2024 [14] - Adjusted non-GAAP profit for Q4 2025 was $26.1 million, or 29.7% of sales, up from 28.4% in Q4 2024 [15] - Full-year adjusted non-GAAP net income was $4.2 million, or $0.31 per share, compared to a loss of $0.6 million, or $0.05 per share in 2024 [19] Business Line Data and Key Metrics Changes - Connected Home channel sales increased by $17.1 million, or 15.8%, to $125.4 million in 2025, driven by new orders in climate control and HVAC [14] - Home entertainment sales decreased by $43.7 million, or 15.2%, to $242.9 million for the full year [15] - In Q4 2025, home entertainment sales were down 23.8% to $58 million, reflecting lower demand for subscription broadcasting products [15] Market Data and Key Metrics Changes - The company noted a slowdown in the connected home market, which began in the second half of 2025, due to industry consolidation in HVAC and shifts in retail demand in Europe [9] - Customer forecasts and orders indicated that revenue inflection in the connected home segment would take longer than expected [10] Company Strategy and Development Direction - The company is focused on restructuring to align with the revenue and margin profile expected for 2026, which includes a reduction in force and cost reductions across various areas [11] - The strategy emphasizes optimizing R&D and portfolio focus on high-revenue and high-margin opportunities [11] - The company aims to improve operational efficiency, strengthen profitability, and generate more free cash flow as part of its long-term strategy [22] Management Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the home entertainment business and the slower-than-expected growth in the connected home segment [8] - The company is adopting a conservative outlook for 2026, expecting a decline in revenue due to market headwinds [20] - Management emphasized the importance of maintaining operational discipline and focusing on profitability amid economic uncertainties [9][22] Other Important Information - The company achieved a positive net cash position for the first time since 2021, with a net cash balance of $8.2 million [19] - The company plans to provide adjusted non-GAAP diluted profit per share guidance in the range of $0.45-$0.65 for 2026 [21] Q&A Session Summary Question: Guidance for 2026 revenue decline - Management could not specify the exact decline percentage but emphasized a focus on improving cash flow and profits [24] Question: Details on expense reductions - Management indicated that significant operating expenses would be reduced holistically to align with revenue [25] Question: Size of the reduction in force (RIF) in Q4 - The RIF in Q4 involved approximately 50 employees [26] Question: Percentage of headcount affected by RIF - Management did not provide a specific percentage but indicated that transitions would occur over time [27][28] Question: Licensing revenue sources in Q4 - Licensing revenue in Q4 was primarily from the traditional home entertainment business, with plans to expand in connected home [31]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $10.9 million, marking a 23% year-over-year growth, and full-year revenue reached $41.1 million, a 22% increase from $33.6 million in 2024 [9][22][23] - The company achieved positive cash flow from operations for both Q3 and Q4, and for the full year, with cash ending at $8.9 million [11][25] - Gross margin for the full year was 62.3%, with a slight reduction of 30 basis points year-over-year due to higher material costs [24][25] Business Line Data and Key Metrics Changes - Domestic core business grew 18% year-over-year in Q4, while international core business saw a significant growth of 71% [9][22] - The PST business decreased by 30% year-over-year, attributed to the timing of contract milestones [22][23] - The recurring global patient base increased by approximately 20% to 59,000 chronic SCIG patients [14] Market Data and Key Metrics Changes - The SCIG market grew approximately 10% in 2025, with KORU's domestic and international core businesses outperforming this growth [9][12] - In Europe, KORU's market share increased from 10% to 20%, with a total addressable market of approximately $50 million [16][35] - The company anticipates significant growth opportunities in the oncology market with the entry of new drugs [29][68] Company Strategy and Development Direction - KORU is focused on three strategic pillars: protecting and growing the core domestic business, expanding internationally, and enabling more drugs to reach more patients [12][62] - The company is diversifying its business with new drug collaborations and entering new therapeutic areas, including oncology [10][15] - The shift from hospital to home care is seen as a significant opportunity for large volume subcutaneous infusion [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, projecting 2026 revenue guidance of $47.5 million to $50 million, representing a growth of 15%-22% [11][26] - The company is prepared for geopolitical risks and anticipates a ramp-up in revenue in the second half of 2026 [27] - Management highlighted the importance of operational excellence programs to maintain margins and manage costs effectively [28] Other Important Information - Linda Tharby announced her retirement effective June 30, 2026, with Adam Kalbermatten set to succeed her as CEO [4][5] - The company received EU MDR certification for the Freedom60 system, enabling the conversion from vials to prefilled syringes [10][16] Q&A Session Summary Question: What does the Freedom60 product do for the market? - The Freedom60 product opens up a $50 million total addressable market in Europe, with significant share gain potential [35][36] Question: Can you provide more detail on the guidance composition? - The guidance range is influenced by the speed of prefill conversions and new drug approvals, with potential impacts from geopolitical factors [64][66] Question: How is the company positioned in Japan? - Japan is seen as a significant market opportunity, with both pumps and consumables approved, and potential growth driven by prefilled syringes [68][70]

Heartbeam (NasdaqCM:BEAT) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsBryan Humbarger - CCORobert Eno - Founder and Executive ChairmanTimothy Cruickshank - CFONone - Company RepresentativeConference Call ParticipantsBill Sutherland - Equity Research AnalystKyle Bauser - Equity Research AnalystLeo Carpio - Equity Research AnalystNone - AnalystOperatorGreetings, and welcome to the HeartBeam Q4 2025 financial results conference call. At this time, all participants are in a listen-only ...

Financial Data and Key Metrics Changes - For Q4 2025, total revenue was $82.4 million, a decrease of 1.3% year-over-year, but an improvement from the double-digit decline in Q3 [10] - Consumables revenue increased to $57.7 million from $56.7 million, representing a growth of 1.7% year-over-year [10] - Device revenue was $24.7 million, down 7.9% year-over-year, but showed improvement compared to Q3 [10] - Adjusted gross margin expanded to 67.4%, while GAAP gross margin increased to 64.4% [11] - Adjusted EBITDA for Q4 was $15 million, up from $9 million in the prior year, marking a significant margin expansion [11] - For the full year, net sales were $300.8 million, down from $334.3 million in 2024, with adjusted EBITDA increasing to $45.1 million from $12.3 million [21][22] Business Line Data and Key Metrics Changes - The company placed over 1,000 devices in Q4, ending the year with over 36,000 systems in the global install base [12] - The installed base is viewed as underutilized, with potential for significant consumables revenue growth through improved utilization [12] Market Data and Key Metrics Changes - The U.S. med spa market has grown from approximately 1,600 locations in 2010 to over 13,000 today, indicating a significant market expansion [7] - Consumer demographics are evolving, with increased engagement from men, Gen Z, and younger consumers seeking skin health treatments [7][8] Company Strategy and Development Direction - The company aims to shift from a device placement model to a device utilization model to drive long-term growth [9] - Key strategic priorities include salesforce excellence, marketing discipline, and focused innovation [14] - The company plans to enhance its commercial model by improving provider education and marketing strategies [16][18] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the demand for non-invasive treatments, despite macroeconomic pressures affecting capital equipment sales [12][39] - The first half of 2026 is expected to be modestly below the prior year, with a stronger trajectory anticipated in the second half [25][28] - The company expects to return to growth in 2027 as operational changes take effect [19][28] Other Important Information - The company has strengthened its balance sheet and improved its cost structure, exiting 2025 in a stronger position than the previous year [20] - The average spend per treatment in the U.S. for consumables is up 10% year-over-year, driven by premium boosters [62] Q&A Session Summary Question: Guidance for 2026 and sales organization overhaul - Management expects revenue to be flat year-on-year, with Adjusted EBITDA slightly below 2025 due to reinvestment in R&D [32][33] Question: Underlying market environment assumptions - Consumer spending remains selective, with a focus on clinically proven results; the aesthetics category has faced pressure due to credit tightness [38][39] Question: Churn trends and marketing to new demographics - Churn improved in Q4 to about 1.1%, with expectations to hold flat year-over-year; marketing strategies are being adjusted to target new demographics [46][49] Question: New system launch timeline and features - The next-generation HydraFacial is planned for launch in 2028, aimed at providing compelling reasons for upgrades [55] Question: Consumables performance and pricing strategy - A 5% price increase on consumables was well-received, and the company is evaluating overall pricing strategy moving forward [76]

Financial Data and Key Metrics Changes - The company reported a net income of $3.8 million for Q4 2025, translating to $0.06 per share, while the full-year net loss was $84.9 million or $1.81 per share [25][26] - Total operating expenses decreased from $112.6 million in 2024 to $86.9 million in 2025, marking a 23% reduction [25] - Cash equivalents and short-term investments decreased from $94.1 million at the end of 2024 to $58.5 million at the end of Q4 2025 [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - The company has also advanced its DNA medicine platform, including promising phase 1 proof of concept data for dMAb technology [21] Market Data and Key Metrics Changes - The market for recurrent respiratory papillomatosis (RRP) treatment is characterized by a significant burden on patients, with many requiring numerous surgeries throughout their lives [15] - Market research indicates that INO-3107 could become the preferred treatment option based on its efficacy and tolerability [16] Company Strategy and Development Direction - The company is focused on optimizing resources to extend its cash runway towards the October 30, 2026 PDUFA date for INO-3107 [24][60] - Strategic partnerships are being leveraged to advance other promising candidates in the pipeline, including collaborations in glioblastoma research [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [7][11] - The company is preparing for a meeting with the FDA to discuss the BLA for INO-3107 and is awaiting feedback on an updated protocol for a confirmatory trial [10][30] Other Important Information - The company has reduced headcount by approximately 15% to conserve financial resources [24] - The FDA has accepted the BLA for INO-3107 under the Accelerated Approval Program, with a standard review timeline of 10 months [5][9] Q&A Session Summary Question: Additional data needed for FDA conversations regarding accelerated approval - Management confirmed that no new clinical data is required, but they have submitted new documentation to the FDA [30] Question: Impact of a potential priority review on launch preparations - The focus is currently on ensuring alignment with the FDA for accelerated approval, with commercial preparations well advanced [34][35] Question: Feedback from KOLs and patients on recent publications - Research indicates a strong preference for INO-3107 based on its efficacy and tolerability, with significant reductions in surgeries reported by patients [37][38] Question: Incorporating learnings from competitor's rollout into distribution strategy - The company is learning from competitor experiences and ensuring that their distribution strategy is well-prepared for launch [42][44] Question: Biological rationale of the dual PD-1/CTLA-4 blockade in partnership with Akeso - The combination aims to enhance immune responses against tumor-associated antigens, building on previous encouraging data [48][49] Question: Plans for INO-3112 if INO-3107 is approved - The company plans to focus resources on INO-3107 first, with potential to advance INO-3112 following approval and available financial resources [55]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company's cash position was approximately $318.1 million, significantly increased from approximately $151.5 million as of December 31, 2024 [29] - Revenue for the fourth quarter of 2025 was $0, down from approximately $11.1 million for the same period in 2024, and full-year revenue for 2025 was also $0 compared to approximately $22.3 million in 2024 [29][30] - Total operating expenses for Q4 2025 were approximately $29.2 million, up from approximately $18.8 million in Q4 2024, and full-year operating expenses for 2025 were approximately $108.1 million compared to approximately $64.8 million in 2024 [30][31] - Net loss for Q4 2025 was approximately $30.2 million, compared to a net loss of approximately $7.1 million in Q4 2024, and the full-year net loss for 2025 was approximately $105 million compared to approximately $40.5 million in 2024 [31] Business Line Data and Key Metrics Changes - The company is focused on advancing Deramiocel toward potential approval for Duchenne muscular dystrophy (DMD) in the U.S., with a Biologics License Application (BLA) under review by the FDA [5][19] - The HOPE-3 trial results indicated a 91% slowing of disease progression in evaluable patients, with statistically significant results in patients with cardiomyopathy [10][11] - The company aims to position Deramiocel to treat as many eligible patients as possible, with a focus on both skeletal and cardiac disease manifestations of DMD [6][7] Market Data and Key Metrics Changes - The FDA has assigned a PDUFA target action date of August 22, 2026, for the review of the BLA for Deramiocel [5][19] - The company is preparing for a potential commercial launch and has completed its FDA pre-license inspection for its manufacturing facility [20][21] - The current manufacturing facility can support approximately 250 patients per year, with plans to expand capacity to accommodate up to 2,500 patients annually by late 2027 [21] Company Strategy and Development Direction - The company is building an infrastructure to support the launch and commercialization of Deramiocel while expanding its pipeline to treat other indications [8][22] - The focus is on executing a disciplined approach to commercialization, including market access, reimbursement planning, and physician education [22] - The company is also exploring expansion into other diseases, initially focusing on Becker muscular dystrophy [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the data supporting Deramiocel's potential benefit in treating DMD, emphasizing the importance of addressing both skeletal and cardiac aspects of the disease [18] - The company is optimistic about its financial position, with sufficient capital to support operations into the fourth quarter of 2027 [27] - Management highlighted the importance of early intervention in DMD treatment and the potential for Deramiocel to be used in younger patients [75] Other Important Information - The company completed a public offering in December 2025, resulting in net proceeds of approximately $162 million [29] - Capricor's common stock was approved for uplisting to the Nasdaq Global Select Market, enhancing visibility within the institutional investment community [28] Q&A Session Summary Question: Anticipation of Ad Comm and Commercial Prep for Deramiocel Approval - Management indicated uncertainty regarding an Ad Comm but expressed confidence in the strength of the HOPE-3 data regardless of whether an Ad Comm occurs [34][35] Question: Labeling Discussions and Expectations - Management noted that labeling discussions have not yet occurred but believes the data supports a label for both DMD and cardiomyopathy [38][52] Question: Cohorts of HOPE-3 Trial and FDA Considerations - Management clarified that the FDA considers Cohort A and Cohort B as one trial and expressed confidence in the statistical significance of Cohort B [44][45] Question: Manufacturing Capacity and Expansion Plans - Management confirmed plans to expand manufacturing capacity to accommodate more patients and emphasized the importance of regulatory compliance [58][70] Question: Early Intervention and Treatment of DMD - Management highlighted the importance of early intervention and the potential for Deramiocel to be used in younger patients, while acknowledging the challenges of obtaining a prevention label [75] Question: European Rights Deal Status - Management indicated that negotiations with NS Pharma for European rights are ongoing and will be prioritized following the PDUFA date [77]